GlycoMimetics (GLYC) Stock Price, News & Analysis

Company Overview

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Key Stats

• Today's Range: $0.20 to $0.23
• 50-Day Range: $0.18 to $0.36
• 52-Week Range: $0.14 to $2.47
• Volume: 567,720 shs
• Average Volume: 6.71 million shs
• Market Capitalization: $14.32 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

GlycoMimetics Stock Analysis - MarketRank™

GlycoMimetics scored higher than 39% of companies evaluated by MarketBeat, and ranked 674th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for GlycoMimetics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for GlycoMimetics are expected to remain at ($0.08) per share in the coming year.

Price to Book Value per Share Ratio

GlycoMimetics has a P/B Ratio of 2.78. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.18% of the float of GlycoMimetics has been sold short.

Short Interest Ratio / Days to Cover

GlycoMimetics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GlycoMimetics has recently decreased by 4.65%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GlycoMimetics does not currently pay a dividend.

Dividend Growth

GlycoMimetics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.55

Percentage of Shares Shorted

4.18% of the float of GlycoMimetics has been sold short.

Short Interest Ratio / Days to Cover

GlycoMimetics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GlycoMimetics has recently decreased by 4.65%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.93

News Sentiment

GlycoMimetics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for GlycoMimetics this week, compared to 1 article on an average week.

Search Interest

1 people have searched for GLYC on MarketBeat in the last 30 days.

MarketBeat Follows

Only 3 people have added GlycoMimetics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GlycoMimetics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.70% of the stock of GlycoMimetics is held by insiders.

Percentage Held by Institutions

75.19% of the stock of GlycoMimetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GLYC Stock Analysis - Frequently Asked Questions

How have GLYC shares performed this year?

GlycoMimetics' stock was trading at $0.2490 at the start of the year. Since then, GLYC shares have decreased by 10.8% and is now trading at $0.2220.
View the best growth stocks for 2025 here.

How were GlycoMimetics' earnings last quarter?

GlycoMimetics, Inc. (NASDAQ:GLYC) issued its quarterly earnings data on Thursday, February, 13th. The biotechnology company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.05.

How do I buy shares of GlycoMimetics?

Shares of GLYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of GlycoMimetics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GlycoMimetics investors own include NVIDIA (NVDA), Viking Therapeutics (VKTX), Bristol-Myers Squibb (BMY), Meta Platforms (META), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 2/13/2025
• Today: 4/15/2025
• Next Earnings (Estimated): 5/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GLYC
• CIK: 1253689
• Web: www.glycomimetics.com
• Phone: (240) 243-1201
• Fax: 301-738-2137
• Employees: 50
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-37,880,000.00
• Net Margins: N/A
• Pretax Margin: -397,340.00%
• Return on Equity: -230.74%
• Return on Assets: -177.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.92
• Quick Ratio: 1.92

Sales & Book Value

• Annual Sales: $10,000.00
• Price / Sales: 1,432.21
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.08 per share
• Price / Book: 2.78

Miscellaneous

• Outstanding Shares: 64,514,000
• Free Float: 58,901,000
• Market Cap: $14.32 million
• Optionable: Optionable
• Beta: 1.74